Utilisation du levosimendan chez l’enfant

Séguéla, Pierre‐Emmanuel; Tafer, Nadir; Thambo, Jean-Benoît; Mauriat, Philippe

doi:10.1016/j.arcped.2016.05.002

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2021

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Levosimendan is a vasodilator alongside the effect of inotrope. Its consumption is spreading in children (13). Its use has not been reported in MIS-C patients.…”

Section: Discussionmentioning

confidence: 99%

A Child with Multiple Inflammatory Syndrome in Children, Stroke and Cardiac Insufficiency

et al. 2021

View full text Add to dashboard Cite

: Multiple inflammatory syndrome in children (MIS-C) is a multisystem inflammatory disease following COVID-19 in children. This disease occurs a few weeks after COVID-19. A child with this condition develops a cytokine release cascade that results in organ damage. The involved organs include the heart, lungs, brain, gastrointestinal tract, and central nervous system. Fever is present in all patients and Kawasaki-like symptoms are one of the common features in these children. In this article, we introduce a child with MIS-C who has skin, gastrointestinal, neurological, and renal symptoms and has been hospitalized in the PICU.

show abstract

“…Levosimendan is a vasodilator alongside the effect of inotrope. Its consumption is spreading in children (13). Its use has not been reported in MIS-C patients.…”

Section: Discussionmentioning

confidence: 99%